Advocates of the Make America Healthy Again agenda have expressed skepticism over President Donald Trump’s agreement with pharmaceutical companies to lower prices and expand access to blockbuster anti-obesity and diabetes medications. 

Following Trump’s Oval Office announcement Thursday about drastically lowering costs for Ozempic and other GLP-1 drugs, MAHA leaders told the Washington Examiner that they would prefer to see an elevation of holistic medicine and improved nutrition quality, rather than pharmaceuticals, as the way to end the obesity epidemic in the United States.